# A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors

> **NCT05678205** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Artiva Biotherapeutics, Inc.**

## Conditions studied

- Breast Cancer
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** AB-201
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT05678205
- **Lead sponsor:** Artiva Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-08-01
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Corporate business decision
- **Last updated:** 2025-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05678205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05678205, "A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05678205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*